Recently, Gao Huimin, Deputy Director of the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (hereinafter referred to as "Lecheng Administration"), and Zhou Lianghui, General Manager of Hainan Boao Lecheng Development Holding Co., Ltd., led a delegation to visit Deep Harbour Cell Valley for an exchange. The theme of this exchange was "Deepening Cooperation in the Field of Cell Therapy and Exploring New Pathways for Industry Development," aiming to promote in-depth collaboration between the two sides in areas such as medical technology innovation, industrial synergy, and policy implementation. The visit sought to jointly explore new pathways for collaborative development in the field of cell therapy between the Guangdong-Hong Kong-Macao Greater Bay Area and the Hainan Free Trade Port, and to enhance the influence of China's cell therapy on the international stage.

Accompanied by Professor Shi Yuanyuan, founder of Deep Harbour Cell Valley, the visiting delegation toured the Cell Valley Smart Exhibition Hall, multi-site collaborative laboratory, and GMP industrial production platform, gaining in-depth insights into its latest advancements in cutting-edge technologies for cell and gene therapy, breakthroughs in key core technologies, and the integration of resources between Shenzhen and Hong Kong. The leadership of the Lecheng Administration highly commended the achievements of Cell Valley in innovative drug development, clinical translation, and international collaboration. They engaged in an in-depth discussion on topics such as the synergistic mechanism between Lecheng's policy advantages and Cell Valley's technological strengths, the establishment of a product quality control system, and pathways for technology transfer.

At the symposium, Professor Shi Yuanyuan extended a warm welcome to the delegation from Lecheng Administration and Lecheng Holdings, and systematically introduced the development layout and phased achievements of Cell Valley. He stated that as the first enterprise in the Guangdong Free Trade Zone to benefit from the national medical openness pilot policy, Deep Harbour Cell Valley has consistently focused on the full-chain innovation of cell therapy, having established a complete system encompassing "basic research—technological breakthroughs—clinical translation—industrial production." As a "testbed" for policy breakthroughs in cell therapy in China, Lecheng Pilot Zone has already formed a first-mover advantage in policy innovation, international resource aggregation, and industrial transformation. In the future, Cell Valley is willing to fully leverage its internationally advanced experience in quality control of cell product production and key core technologies to actively support Lecheng in building a national pilot hub for cell therapy.

Deputy Director Gao Huimin introduced the implementation achievements of the Lecheng Pilot Zone in core policies such as "Import of Licensed Drugs and Medical Devices,"  "Real-world data application," and "Biomedical New Technologies." He pointed out that the technological accumulation of Deep Harbour Cell Valley and the policy advantages of Lecheng are highly complementary. He expressed expectations for pragmatic cooperation between the two parties in clinical research of cell therapy products, cross-border applications, and upstream-downstream collaboration, aiming to jointly accelerate the translation of technological achievements and benefit more patients.

General Manager Zhou Lianghui elaborated on the latest progress of Lecheng Development Holding Company in establishing the Boao Public Service Center for Cell Therapy from the perspective of industrial carrier and capital linkage. He stated that Lecheng is accelerating the construction of an integrated service platform covering R&D, production, quality control, and other processes to facilitate the efficient implementation of healthcare projects. In the future, he expressed the hope to establish closer collaborative relationships with Deep Harbour Cell Valley in regional coordination, resource sharing, and the implementation of innovative projects, aiming to jointly create a cross-regional industrial collaboration demonstration benchmark.

Both parties unanimously agreed to leverage this exchange as an opportunity to further strengthen strategic coordination, fully harness the synergistic effects of policy innovation and technological breakthroughs, and deepen cooperation in areas such as cutting-edge technology R&D, clinical application translation, and international resource integration. Together, they aim to propel China's medical technology innovation and industrialization to achieve leapfrog development.